Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant CDX-1140 and Cemiplimab in Stage III-IV Head and Neck Cancer Prior to Surgery
NCT06980038Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2026
- Primary completion
- Nov 2027
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of CDX-1140 in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Incidence of adverse events and Major pathologic response. Started May 2026; status: recruiting.
02
Drugs
CDX-1140
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06980038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06980038.